Alterity Therapeutics Ltd (ASX: ATH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Alterity Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$55.00 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
229.10 million
Earnings per share
-0.111
Dividend per share
N/A
Year To Date Return
-33.75%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Alterity Therapeutics Ltd (ASX: ATH)
Latest News
Healthcare Shares
Why the Alterity (ASX:ATH) share price is skyrocketing 42% today
ASX Share Market News
Here's why the Alterity Therapeutics (ASX:ATH) share price blasted 20% higher today
ASX Share Market News
Why Alterity Therapeutics (ASX:ATH) share price has surged up 27% today
ASX Share Market News
Alterity (ASX:ATH) share price lower on completed placement
⏸️ Investing
Why Alterity Therapeutics' share price has rocketed 96% in 2 days
ASX Share Market News
Alterity Therapeutics share price rockets 70% on new data
ASX Share Market News
Why Etherstack and these shares were the most traded on the ASX last week
ATH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Alterity Therapeutics Ltd
Alterity Therapeutics Ltd. engages in the research and development into Parkinsonian and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.
ATH Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 02 Nov 2026 | $0.26 | $-0.01 | -3.77% | 37,809 | $0.26 | $0.26 | $0.25 |
| 30 Oct 2026 | $0.27 | $0.01 | 3.85% | 368,385 | $0.26 | $0.27 | $0.24 |
| 29 Oct 2026 | $0.26 | $0.02 | 8.33% | 210,297 | $0.25 | $0.26 | $0.25 |
| 28 Oct 2026 | $0.24 | $0.00 | 0.00% | 143,725 | $0.24 | $0.25 | $0.24 |
| 27 Oct 2026 | $0.24 | $-0.03 | -11.32% | 102,728 | $0.26 | $0.26 | $0.24 |
| 26 Oct 2026 | $0.27 | $0.01 | 3.92% | 235,561 | $0.26 | $0.27 | $0.24 |
| 23 Oct 2026 | $0.26 | $-0.01 | -3.77% | 134,037 | $0.26 | $0.26 | $0.23 |
| 22 Oct 2026 | $0.27 | $0.01 | 3.92% | 395,725 | $0.27 | $0.27 | $0.25 |
| 21 Oct 2026 | $0.26 | $-0.02 | -7.41% | 761,733 | $0.27 | $0.27 | $0.24 |
| 20 Oct 2026 | $0.27 | $-0.05 | -15.63% | 606,640 | $0.30 | $0.30 | $0.27 |
| 19 Oct 2026 | $0.32 | $0.01 | 3.23% | 281,708 | $0.31 | $0.32 | $0.28 |
| 16 Oct 2026 | $0.31 | $0.00 | 0.00% | 806,492 | $0.31 | $0.32 | $0.30 |
| 15 Oct 2026 | $0.31 | $-0.02 | -6.15% | 746,578 | $0.33 | $0.33 | $0.30 |
| 14 Oct 2026 | $0.33 | $-0.02 | -5.88% | 51,488 | $0.34 | $0.34 | $0.32 |
| 13 Oct 2026 | $0.34 | $-0.01 | -2.86% | 2,288,148 | $0.35 | $0.35 | $0.34 |
| 12 Oct 2026 | $0.35 | $-0.01 | -2.82% | 455,791 | $0.36 | $0.37 | $0.34 |
| 09 Oct 2026 | $0.36 | $-0.01 | -2.74% | 334,282 | $0.38 | $0.38 | $0.35 |
| 08 Oct 2026 | $0.37 | $-0.02 | -5.26% | 188,623 | $0.38 | $0.40 | $0.36 |
| 07 Oct 2026 | $0.38 | $-0.02 | -5.00% | 560,606 | $0.40 | $0.41 | $0.37 |
| 06 Oct 2026 | $0.40 | $0.03 | 8.11% | 340,800 | $0.37 | $0.40 | $0.37 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 31 Aug 2026 | Paul Marks | Exercise | 47,620 | $24,048 |
Exercise of options.
|
| 31 Aug 2026 | David Stamler | Expiry | 47,620 | $24,048 |
Options expired.
|
| 15 Jun 2026 | Julian Barbaczy | Issued | 2,000,000 | $1,020,000 |
Issue of options.
|
| 15 Jun 2026 | Lawrence Gozlan | Issued | 1,000,000 | $510,000 |
Issue of options.
|
| 06 Jan 2026 | David Stamler | Expiry | 91,392,720 | $822,534 |
Options expired.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Peter Ashley Marks | Non-Executive Director | Jul 2005 |
Mr Marks has over 35 years of experience in corporate advisory and investment banking, in capital raisings, IPOs, cross-border transactions, mergers and acquisitions, corporate underwriting, and venture capital transactions involving companies in Australia, the United States, and Israel. He is the member of the Share Plan Committee.
|
| Mr Lawrence Bernard Gozlan | Non-Executive Director | Aug 2011 |
Mr Gozlan is a biotechnology investor and advisor and is the Chief Investment Officer and Founder of Scientia Capital, a global investment fund focused on life sciences. Scientia Capital was established to provide expertise and manage investments for net-worth individuals, family offices, and institutional investors seeking exposure to the biotechnology industry. He previously worked as the Senior Biotechnology Analyst in the equities team at Foster Stockbroking Pty Ltd and gained senior corporate finance experience advising life sciences companies at Deloitte. He is the member of the Share Plan Committee.
|
| Mr Julian Barbaczy | Non-Executive ChairmanNon-Executive Director | Nov 2025 |
Mr Babarczy is an investment executive and company director with over 25 years of experience in Australia's financial markets. He spent over a decade in senior leadership roles at Regal Partners, contributing to the firm's growth from a boutique fund manager to a multi-billion-dollar investment house, where he led or contributed to a range of investment portfolios range of sectors. He is the member of the Share Plan Committee.
|
| Ms Ann Cunningham | Non-Executive Director | Apr 2026 |
Ms Cunningham brings more than 25 years of global pharmaceutical and biotechnology experience to Alterity. She is the Founder and Chief Executive Officer of i3 Strategy Partners, a pharmaceutical consulting group focused on health outcomes through patient strategies, particularly within underserved communities. Ms. Cunningham has advised senior pharmaceutical and biotechnology executives on planning and executing portfolio strategies and brand launches. She also led the commercial development of a product portfolio as Vice President of Neurodegenerative Disease and Psychiatry at Teva Pharmaceutical Industries.
|
| Ms Abby Macnish Niven | Company Secretary | Nov 2024 |
-
|
| Dr David Stamler | Chief Executive Officer | Jan 2021 |
-
|
| David Stamler | Chief Executive Officer |
-
|
|
| Abby Macnish Niven | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 63,607,727 | 29.11% |
| Citicorp Nominees Pty Limited | 26,006,687 | 11.90% |
| UBS Nominees Pty Ltd | 14,456,191 | 6.62% |
| J P Morgan Nominees Australia Pty Limited | 10,271,145 | 4.70% |
| BNP Paribas Noms Pty Ltd | 8,137,064 | 3.72% |
| Jagen Nominees Pty Ltd <The B Liberman Family A/C>-i | 5,531,474 | 2.53% |
| Neweconomy Com Au Nominees Pty Limited <900 Account> | 5,201,814 | 2.38% |
| HSBC Custody Nominees (Australia) Limited – A/C 2 | 5,049,274 | 2.31% |
| BNP Paribas Noms (NZ) Ltd | 3,598,764 | 1.65% |
| Orchid Bay Investments Pty Ltd <Orchidbay Investments A/C> | 3,068,182 | 1.40% |
| Morgan Stanley Australia Securities (Nominee) Pty Limited | 2,382,130 | 1.09% |
| ONE Managed Investment Funds Limited <Ti Growth A/C> | 2,250,000 | 1.03% |
| Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> | 2,173,247 | 0.99% |
| Jagen Nominees Pty Ltd <The B Liberman Family A/C>-ii | 1,735,044 | 0.79% |
| Just Group Investment Pty Ltd <Just Group Investment A/C> | 1,666,667 | 0.76% |
| Palm Beach Nominees Pty Ltd | 1,608,129 | 0.74% |
| BNP Paribas Nominees Pty Ltd <IB AU Noms Retail Client> | 1,248,396 | 0.58% |
| Mrs Amanda Kay Lang | 1,246,742 | 0.57% |
| Dramista Pty Ltd <Bep Self Managed Sf A/C> | 1,230,000 | 0.56% |
| Andrew Mark Wilmot Seton | 962,968 | 0.45% |
